RGN Human

Regucalcin, also known as Senescence Marker Protein-30 (SMP30), is a calcium-binding protein that plays a crucial role in calcium signaling regulation. It was first discovered in 1978 and is encoded by the rgn gene located on the X chromosome in both humans and other vertebrates . Unlike other calcium-binding proteins, regucalcin lacks the EF-hand motif, which is typically involved in calcium binding .

Regucalcin is involved in various cellular processes, including:

• Calcium Homeostasis: It helps maintain intracellular calcium levels, which are vital for numerous cellular functions.
• Gene Expression Regulation: Regucalcin is transported to the nucleus, where it regulates DNA and RNA synthesis and gene expression .
• Enzyme Regulation: It inhibits several key enzymes, such as protein kinases, protein phosphatases, cysteinyl protease, nitric oxide synthase, and aminoacyl-tRNA synthetase .
• Cell Proliferation: Overexpression of regucalcin has been shown to inhibit cell proliferation in both normal and cancer cells .

Recent studies have highlighted the potential role of regucalcin in cancer suppression. It has been observed that regucalcin expression is significantly downregulated in tumor tissues of cancer patients . Patients with higher levels of regucalcin in their tumor tissues tend to have longer survival rates . Overexpression of regucalcin can suppress the development of carcinogenesis, making it a promising target for cancer therapy .

Human recombinant regucalcin is produced using recombinant DNA technology, which involves inserting the human regucalcin gene into a suitable expression system, such as bacteria or yeast. This allows for the large-scale production of regucalcin for research and therapeutic purposes.